Skip to content. | Skip to navigation

National Cancer Institute U.S. National Institutes of Health


Personal tools

You are here: Home / Biomarkers / CDCP1



This biomarker is also known as:
  • CUB domain containing protein 1,
  • Transmembrane and associated with src kinases,
  • TRASK,
  • CD318 antigen,
  • Membrane glycoprotein gp140,
  • transmembrane and associated with src kinases,
  • SIMA135,
  • CUB domain-containing protein 1,
  • Subtractive immunization M plus HEp3-associated 135 kDa protein,
  • CD318,
  • subtractive immunization M plus HEp3-associated 135 kDa protein,
  • membrane glycoprotein gp140,
  • Q9H5V8,

View in BioMuta


CDCP1 is a transmembrane protein containing three extracellular CUB domains. It is found to be overexpressed in colon and lung cancers. Its expression level is correlated with the metastatic ability of carcinoma cells. CDCP1 is located on the cell surface and may be involved in cell adhesion and cell matrix association. Alternatively spliced transcript variants encoding distinct isoforms have been reported.


QA State: Curated
Type: Protein
Short Name:


There are no datasets associated with this biomarker.


The following organs have data associated with this biomarker…



Phase: Two
QA State: Under Review


CDCP1 is a transmembrane tumor vascular marker (TVM) that is selectively expressed in tumor vasculature and represents a promising target for vascular imaging or anti-vascular therapy of epithelial ovarian cancer.

Performance Comment

CDCP1 was one of 13 genes out of 50 selected for further validation in PMID:21617380. Average expression of CDCP1 was significantly higher in epithelial ovarian cancer tumors than any other normal tissue tested.


This biomarker is currently being annotated or is under review. You must be logged in or do not have permission to view any additional information. Contact Heather Kincaid at if you should have access to this biomarker.

2016 EDRN PI Orientation

The New and Continuing EDRN Principal Investigator Orientation will take place March 14–15, 2016 in Bethesda, Maryland.

Announcement 11/05/2015

Thank you to everyone who made the 29th EDRN Steering Committee Meeting a success. The orientation for new and continuing EDRN PIs will be held Monday-Tuesday, March 14-15, 2016, on the NCI campus. More information will be available later this autumn.

Announcement 06/30/2015

A funding opportunity for a new pancreatic cancer initiative, called The Pancreatic Cancer Detection Consortium (U01), has been released. For more information, please go to /grants/guide/ pa-files/ PAR-15-289.html.